
Intensity Therapeutics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
SHELTON, Conn., March 6, 2026 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology…
Read More











